REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section of Talis Biomedical’s website at investors.talisbio.com. Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before the start of the call to obtain a unique pin for the call.
The webcast will be archived and will be available for replay via the News & Events page following the call.
About Talis Biomedical
Talis Biomedical is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The company plans to develop and commercialize innovative products on its sample-to-answer Talis One® system to enable accurate, low cost, and rapid molecular testing. For more information, visit talisbio.com.
Contact
Media & Investors
Emily Faucette
This email address is being protected from spambots. You need JavaScript enabled to view it.
415-595-9407
| Last Trade: | US$1.85 |
| Daily Volume: | 0 |
| Market Cap: | US$3.370M |
November 14, 2023 August 10, 2023 August 02, 2023 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
